Participants with any concomitant or prior invasive malignancies are ineligible with the following exceptions:\r\n* Treated limited-stage basal cell or squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the breast or cervix\r\n* Prior cancer treated with curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence
Patients must be disease-free of prior invasive malignancies for >  years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\r\n* NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy greater than or equal to  months prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the past  months: carcinoma in situ of the cervix, and basal cell and squamous cell carcinoma of the skin.
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treatment stage I or II cancer from which the patient is in complete remission; patients with other malignancies must also be disease free for at least three years
Patients must be free of any prior malignancies for >=  year\r\n* NOTE: the exception to this would be currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage ) with histologically confirmed free margins of excision
Patients must be free of any prior malignancies for >=  year; NOTE: the exception to this would be currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage ) with histologically confirmed free margins of excision; in addition, it is well-recognized that patients at highest risk for EBV-related lymphoma (ie, those with chronic immunosuppression) are also at high risk for various malignancies, both invasive and non-invasive; therefore, exceptions may also be granted on a case-by-case basis, at the discretion of the PI with approval from the Data Monitoring Committee, for those patients with good clinical control of active malignancy, if the EBV-related lymphoma is considered to be a more immediate threat to the subjects health and/or life
Disease-free of active second/secondary or prior malignancies for ? years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast; patients with early stage of prostate cancer under clinical surveillance without therapy are eligible
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treated stage I or II cancer from which the patient is in complete remission; patients with other prior malignancies must be disease-free for >= three years
Free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Prior history of non-breast malignancies unless they have been disease free for  or more years and are deemed by their physician to be at low risk for recurrence. Further, patients who have the following cancers treated within the prior  years are permitted: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, basal cell or squamous cell carcinoma of the skin.
Disease free of prior malignancies for >=  years with exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
ARM I&II: Patients must have no concurrent malignancy except curatively treated early stage bladder and prostate cancer that has been completed resected, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treated stage I or II cancer from which the patient is in complete remission. Patients with other prior malignancies must be disease free for >=  years
Disease free of prior malignancies for >  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast; patients with early stage of prostate cancer under clinical surveillance without therapy are eligible; patients with B-cell lymphomas treated with curative intent, and in remission for at least  years, may be in included (after discussion with principal investigator [PI])
Patients with a previous history of non-breast malignancy are eligible only if they meet the following criteria for a cancer survivor: (), and ()\r\n* Has undergone potentially curative therapy for all prior malignancies\r\n* Has been considered disease-free for at least  year (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix)
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Disease-free of prior malignancies for >=  years with the exception of basal or squamous cell skin carcinoma, carcinoma in situ of the breast or cervix, or localized prostate cancer (treated definitively with hormone therapy, radiotherapy, or surgery)
Free of prior malignancies for  years with exception of patients diagnosed with basal cell or non-metastatic squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast, who are eligible even if they are currently treated or were treated and/or diagnosed in the past  years prior to study enrollment.
Prior history of malignancies unless the patient has been disease free for >=  years; exceptions include basal cell carcinoma or squamous cell carcinoma of the skin; carcinoma in situ of cervix; carcinoma in situ of breast, localized prostate cancer, or superficial bladder cancer that has undergone curative therapy
Patients with any other concomitant or prior invasive malignancies are ineligible; however, patients with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible
Patients with concomitant or prior invasive malignancies within the past  years; subjects with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible
Disease free of prior malignancies for >=  years with the exception of:\r\n* Currently treated squamous cell and basal cell carcinoma of the skin, or\r\n* Carcinoma in situ of the cervix, or\r\n* Surgically removed melanoma in situ of the skin (stage ) with histological confirmed free margins of excision, or\r\n* Prostate cancer (Ta or Tb using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured, or\r\n* Any other malignancy that has/have been curatively treated with surgery and/or localized radiation
Patients with additional (other than AML) active malignancies, other than curatively treated carcinoma in situ (CIS) of the cervix, or basal or squamous cell carcinoma of the skin; patients are not considered to have a \currently active\ malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for >  years
Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast; patients with history of prior malignancies should be free of disease for at least  years to be eligible for this study
Concurrent malignancies except basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ treated with curative intent; any cancer from which the patient has been disease free for at least  years is permissible
Prior history of malignancies, other than MDS or AML, unless the subject has been free of the disease for >=  year; however, subjects with the following history/concurrent conditions are allowed: basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histologic finding of prostate cancer (Ta or Tb using the tumor, node, metastasis [TNM] clinical staging system)
Diagnosis of prior malignancy within the past  years with the exception of successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast; history of other malignancies are allowed if in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy >  years
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients with any other concomitant or prior invasive malignancies are ineligible; however, patients with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients with any other concomitant or prior invasive malignancies are ineligible; however, patients with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT  ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients with any other concomitant or prior invasive malignancies are ineligible, however, patients with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast are eligible
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nPatients with any other concomitant or prior invasive malignancies are ineligible; however, patients with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible
Disease free of prior malignancies with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated
The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor; a cancer survivor is eligible provided the following criteria are met: () patient has undergone potentially curative therapy for all prior malignancies, () patients have been considered disease free for at least  year (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix)
The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor; a cancer survivor is eligible provided the following criteria are met: \r\n* Patient has undergone potentially curative therapy for all prior malignancies\r\n* Patients have been considered disease free for at least  year (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix)
Disease free of prior malignancies for >  years with exception of currently treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Disease free of prior malignancies for  years with exception of currently treated basal cell squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast; patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received
COHORT II: Patients with a history of non-breast malignancies are eligible if they have been disease free for  or more years prior to enrollment and are deemed by their physicians to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past  years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin
Newly diagnosed MCL: Disease free of prior malignancies of equal to or greater than  months with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy >  years
Patients with active malignancy of other type than required for this study, are not eligible with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast; patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received
Disease-free of prior malignancies for >=  years with the exception of basal or squamous cell skin carcinoma, carcinoma in situ of the breast or cervix, or localized prostate cancer (treated definitively with hormone therapy, radiotherapy, or surgery)
Disease free of other malignancies beside the AML or myelodysplastic syndrome (MDS) for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in situ\ of the cervix or breast
No concurrent active malignancies are allowed on study for >=  years prior to treatment start with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast
Patients with a history of non-breast malignancies are eligible if they have been disease-free for  or more years prior to enrollment and are deemed by their physician to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past  years; carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin
Disease free of prior malignancies for ?  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \insitu\ of the cervix or breast
A concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; subjects with prior malignancies must be disease-free for >= five years
Patients must be disease free of any prior malignancies for >=  years\r\n* The exception to this would be currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage ) with histologically confirmed free margins of excision
Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for >=  years with the exception of the following malignancies:\r\n* Basal cell carcinoma of the skin\r\n* Squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the cervix\r\n* Carcinoma in situ of the breast\r\n* Incidental histologic finding of prostate cancer (Ta or Tb using the tumor, node, metastasis [TNM] clinical staging system) or prostate cancer that is curative
Disease free of prior malignancies for >=  years with the exception of:\r\n* Currently treated squamous cell and basal cell carcinoma of the skin, or\r\n* Carcinoma in situ of the cervix, or\r\n* Surgically removed melanoma in situ of the skin (stage ) with histological confirmed free margins of excision , or\r\n* Prostate cancer (Ta or Tb using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured, or \r\n* Any other malignancy that has/have been curatively treated with surgery and/or localized radiation
Disease free of prior malignancies of equal to or greater than  months with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy >  years.
FOR TISSUE COLLECTION TO ESTABLISH PDX (PART ): Disease free of other prior malignancies of >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy) or not actively being treated, with a life expectancy >  years.
Patients must be disease-free of prior invasive malignancies for >  years prior to registration with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Prior history of malignancies, other than multiple myeloma (MM), unless the patient has completed definitive treatment and has been free of the disease for >=  years; patients who are free of disease <  years may enroll after discussion with the principal investigator; exceptions include the following (i.e. the following are eligible to participate):\r\n* Basal or squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the cervix\r\n* Ductal carcinoma in situ of the breast\r\n* Incidental histologic finding of prostate cancer (Ta or Tb) managed with surveillance
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >=  years
Patients with a prior history of malignancies, other than multiple myeloma, are excluded unless the subject has been free of the disease for >=  years with the exception of the following non-invasive malignancies: \r\n* Basal cell carcinoma of the skin \r\n* Squamous cell carcinoma of the skin \r\n* Carcinoma in situ of the cervix \r\n* Carcinoma in situ of the breast \r\n* Incidental histological findings of prostate cancer (Ta or Tb using the TNM [tumor, nodes, metastasis] clinical grading system) or prostate cancer that is curative
Patients must be disease free of prior invasive malignancies for >  years, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or cancer in-situ of the cervix
Patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible; patients with stage IA endometrial cancer are eligible if the following conditions are met: without vascular or lymphatic invasion AND no serous, clear cell or grade  histology; patients with early stage I or II cancers treated with curative intent who have no evidence of recurrent cancer  years following diagnosis and judged by the investigator to be at low risk or recurrence are eligible
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
No other malignancies in addition to AML that are currently requiring treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= three years prior to registration
Has a prior history of malignancies, other than MM, unless the subject has been free of the disease for ?  years (with the exception Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer [Ta or Tb] or prostate cancer that is curative)
Prior history of cancer, other than MDS, unless the subject has been free of the disease for ?  years. (Basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and incidental histologic finding of prostate cancer) (Ta or Tb using the tumor, nodes, metastasis [TNM] clinical staging system is allowed)
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder. Patients with prior malignancies must be disease-free for five years.
Has a prior history of malignancies, other than MM, unless the subject has been free of the disease for ?  years (with the exception Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer [Ta or Tb] or prostate cancer that is curative)
Patients with prior malignancies are eligible if they have been disease-free for at least  years and are deemed by their physician to be at low risk for recurrence. Patients with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have been effectively treated are eligible, even if these conditions were diagnosed within  years of randomization.
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Patients with active malignancy of other type than required for this study are not eligible with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in situ\ of the cervix or breast; patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received
Patients with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible; patients with stage IA endometrial cancer are eligible if the following conditions are met: without vascular or lymphatic invasion AND no serous, clear cell or grade  histology; patients with early stage I or II cancers treated with curative intent who have no evidence of recurrent cancer  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible
Disease-free of active second/secondary or prior malignancies for ?  years with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.
Disease free of prior malignancies of equal to or greater than  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast, or other malignancies in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy >  years
Disease free of prior malignancies for >=  years with exception of treated basal cell or squamous cell carcinoma of the skin; carcinoma in situ of the cervix or breast, or low-risk localized prostate cancer does not outright exclude patients, but such cases need to be discussed with Dr. Zonder prior to enrollment
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Disease free of prior malignancies for > =  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast, or localized prostate cancer.
Patient must be disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Prior history of other malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless disease free for > =  years.
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in situ\ of the cervix or breast
Patients must be disease-free of prior invasive malignancies for >=  years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Subjects with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible; subjects with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; subjects with any other concomitant or prior invasive malignancies are ineligible
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in situ\ of the cervix or breast or low risk prostate cancer after curative therapy
Previous or concomitant malignancy, except for basal-cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix. Subjects with other malignancies are eligible if they have remained disease free for at least  years prior to study entry;
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Other malignancies unless the patient is considered to be disease-free for  or more years prior to randomization and is deemed by the physician to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past  years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell or squamous cell carcinoma of the skin
Disease-free of active second/secondary or prior malignancies for equal to or more than (>=)  year with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast
Disease free of other malignancies beside the AML for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in situ\ of the cervix or breast
Disease-free period of >  years from any other previous malignancies, excluding curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
Subjects with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible; subjects with prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence are eligible; subjects with any other concomitant or prior malignancies are ineligible
Disease free of prior malignancies for >=  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
Disease-free of active second/secondary or prior malignancies for equal to or over  years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in-situ\ of the cervix or breast
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Diagnosis of prior malignancy within the past  years with the exception of successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma \in situ\ of the cervix or breast; history of other malignancies are allowed if in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy >  years
Patients must be disease-free of other prior invasive malignancies for >=  years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; prior early stage breast cancers are also allowed as long as prior treatment did not include aromatase inhibitors
Patients with previous or concomitant non-breast invasive malignancy; exceptions are limited exclusively to patients with the following previous malignancies, if adequately treated: basal or squamous cell carcinoma of the skin, in situ non-breast carcinoma, contra- or ipsilateral in situ breast carcinoma, stage Ia carcinoma of the cervix
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Disease free of prior malignancies for  years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \in situ\ of the cervix or breast; patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received
Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease or >=  years with the exception of the following malignancies\r\n* Basal cell carcinoma of the skin\r\n* Squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the cervix\r\n* Carcinoma in situ of the breast\r\n* Incidental histologic finding of prostate cancer (Ta or Tb using the TNM clinical staging system) or prostate cancer that is curative
A patient with a history of a previous malignancy is eligible for this study as long as the patient meets the following criteria for a cancer survivor; a cancer survivor is eligible provided that the following criteria are met: \r\n* The patient has undergone potentially curative therapy for all prior malignancies; \r\n* There has been no evidence of any prior malignancies for at least five years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone); and \r\n* The patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies
If a patient is a cancer survivor, the patient must have undergone potentially curative therapy for all prior malignancies, with no evidence of prior malignancy for at least  years (except for effectively treated basal cell or squamous cell carcinoma of the skin, or carcinoma-in-situ of the cervix treated by surgery alone)
